Hinge Health rallies 64.6% as Q2 revenue jumps 53%

Hinge Health shares surged 64.6% in three months as Q2 revenue rose 53% to $212.8 million, with operating margin up 1,000 basis points.

"Better-than-expected billings were driven by stronger yield, while eligible lives and average selling price tracked prior expectations," management said in the Q2 earnings release.

Last-12-month calculated billings reached $861.8 million, up from $568.4 million a year earlier. The client base expanded to 2,929 from 2,359. Adjusted gross profit climbed 60.7% to $185.3 million, with adjusted gross margin at 87%, up 400 basis points. Adjusted operating income rose 135.7% to $61.5 million, and free cash flow totaled about $100 million in the quarter.

The company raised full-year 2026 revenue guidance to $856-$860 million from $798-$804 million, and adjusted operating income guidance to $236-$244 million from $217-$227 million. Management now expects full-year yield of about 4.45%. Third-quarter revenue guidance of $223-$225 million implies 45% year-over-year growth at the midpoint, keeping the near-term growth bar elevated.

Hinge Health's expansion into new care areas supports the growth trajectory. Migraine adoption reached more than 450 clients covering more than 5 million eligible lives, and HingeSelect expanded beyond 5,000 provider locations, broadening the company's reach across care pathways. The planned $105 million acquisition of Cylinder Health adds gastrointestinal care, nearly 100 clients and about 2 million lives. Omada Health also addresses musculoskeletal and cardiometabolic conditions, highlighting the broader push toward multi-condition virtual care.

The raised outlook depends increasingly on yield, renewals and sales-pipeline conversion. Hinge Health must also integrate Cylinder, invest ahead of a broader gastrointestinal rollout and maintain commercial momentum as expectations rise. Competition for employer and health-plan budgets remains relevant, with Teladoc Health marketing integrated virtual-care offerings across several care categories, reinforcing the need for Hinge Health to sustain differentiation, partner access and implementation quality.

HNGE carries a Zacks Rank #3 (Hold), with a Growth Score of A and a Value Score of D, according to Zacks Investment Research. The Growth Score highlights favorable growth prospects, while the Value Score suggests the shares are not particularly attractive on valuation metrics. The stock's 64.6% advance is backed by faster revenues, wider margins and a higher 2026 outlook, but the counterweight is a tougher execution hurdle as the company expands into new programs and allocates capital across growth, acquisitions and repurchases.

The guidance raise shows management expects demand for virtual musculoskeletal care to accelerate. Investors will watch Q3 results for evidence that yield growth and Cylinder integration can sustain the current valuation.

This article is for informational purposes only and does not constitute investment advice.